Uncategorized

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

Published

on

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version